Journey Medical Corporation: Why It Might Be Worth Having A Skin In This Game
Journey Medical's newly approved Emrosi™ outperformed Oracea® in two Phase III trials. If it captures a significant share of Oracea's $300m market, Journey could be significantly undervalued.